SCHEMBL600897

SCHEMBL600897

CCCCCCC=CC(C)(N)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.58
CYP2C19 P33261 3/20 0.58
BLM P54132 3/20 0.58
HSD17B10 Q99714 3/20 0.58
GMNN O75496 2/20 0.58
USP2 O75604 2/20 0.58
POLB P06746 2/20 0.58
CYP3A4 P08684 2/20 0.58
CYP2C9 P11712 2/20 0.58
APEX1 P27695 2/20 0.58
RECQL P46063 2/20 0.58
CYP2D6 P10635 1/20 0.58
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
PPARG P37231 3/20 0.50
PPARD Q03181 3/20 0.50
PPARA Q07869 3/20 0.50
MAPT P10636 2/20 0.50
FABP4 P15090 2/20 0.50
FAAH O00519 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14322640 1.00 CYP1A2 (0.58) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL600896 1.00 CYP1A2 (0.58) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL20680343 0.98 CYP1A2 (0.56) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL19357333 0.98 CYP1A2 (0.56) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL16401654 0.93 CYP2C19 (0.49) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL16401332 0.93 CYP2C19 (0.49) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL16401330 0.93 CYP2C19 (0.49) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL23534464 0.85 CYP2C19 (0.43) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL366778 0.85 CYP2C19 (0.43) CYP1A2CYP2C19BLMHSD17B10GMNN
SCHEMBL366777 0.85 CYP2C19 (0.43) CYP1A2CYP2C19BLMHSD17B10GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720088-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS University of Georgia Research Foundation, Inc. (US) 2026-04-08 EP claimed
EP-4713348-A1 DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 University of Georgia Research Foundation, Inc. (US) 2026-03-25 EP claimed
WO-2025245225-A1 STAPLED PEPTIDE PROTEOLYSIS TARGETING CHIMERAS (SP-PROTACS) AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-11-27 WO claimed
US-12391733-B2 Stapled intracellular-targeting antimicrobial peptides to treat infection DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-08-19 US claimed
WO-2025085624-A1 INHIBITORS OF RAB-RILPL INTERACTIONS AND USES THEREOF UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2025-04-24 WO claimed
EP-3986438-B1 P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES MERCK SHARP & DOHME LLC (US) 2025-04-16 EP claimed
US-12264185-B2 Stabilized BCL9 peptides for treatment of aberrant Wnt signaling WNTRX PHARMACEUTICALS INC. (US) 2025-04-01 US claimed
WO-2024243509-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-11-28 WO claimed
EP-4467153-A1 CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS University of Georgia Research Foundation, Inc. (US) 2024-11-27 EP claimed
WO-2024238623-A1 DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-11-21 WO claimed
US-20150291682-A1 MIMETIC PEPTIDES LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) 2015-10-15 US claimed
EP-2917234-A1 MIMETIC PEPTIDES Les Hôpitaux Universitaires de Genève (CH) 2015-09-16 EP claimed
US-8940864-B2 Stabilized therapeutic small helical antiviral peptides NEW YORK BLOOD CENTER, INC. (US) 2015-01-27 US claimed
US-8933019-B2 Antiviral cell-penetrating peptides NEW YORK BLOOD CENTER, INC. (US) 2015-01-13 US claimed
WO-2014072916-A1 MIMETIC PEPTIDES LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) 2014-05-15 WO claimed
US-20130059776-A1 Antiviral Cell-Penetrating Peptides NEW YORK BLOOD CENTER 2013-03-07 US claimed
US-8324153-B2 Antiviral cell-penetrating peptides NEW YORK BLOOD CENTER, INC. (US) 2012-12-04 US claimed
EP-2283033-A1 ANTIVIRAL CELL PENETRATING PEPTIDES New York Blood Center (US) 2011-02-16 EP claimed
US-20090281041-A1 ANTIVIRAL CELL-PENETRATING PEPTIDES NEW YORK BLOOD CENTER 2009-11-12 US claimed
WO-2009137532-A1 ANTIVIRAL CELL PENETRATING PEPTIDES NEW YORK BLOOD CENTER (US) 2009-11-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059776-A1 Antiviral Cell-Penetrating Peptides ZC3HAV1, MAVS, HAVCR2 CYP1A2 4845/4885CYP2C19 4477/4885BLM 3694/4885
US-12391733-B2 Stapled intracellular-targeting antimicrobial peptides to treat infection VIP, SPPL2B, HM13 CYP1A2 4876/4885CYP2C19 4707/4885BLM 3040/4885
US-20090281041-A1 ANTIVIRAL CELL-PENETRATING PEPTIDES ZC3HAV1, MAVS, HAVCR2 CYP1A2 4845/4885CYP2C19 4477/4885BLM 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.